VAXIGRIP is an inactivated split virion (split virus) Influenza vaccine. It is trivalent and is indicated for active immunization against Influenza caused by Influenza Viruses contained in the vaccine. 2016-17 strains of attenuated influenza viruses included are:
- A/California/7/2009 NYMC X-179A (A/California/7/2009 [H1N1]pdm09 – like),
- A/Hong Kong/4801/2014 NYMCX-263B (A/Hong Kong/4801/2014[H3N2]-like),
Its is licensed to be used in children 6 months of age and older and in adults. Although the current influenza vaccine can contain one or more of the antigens administered in previous years, annual vaccination using the current vaccine is necessary because immunity declines in the year following vaccination. The vaccine is prepared from virus grown in the allantoic cavity of embryonated eggs. No adjuvant or preservative is added in single dose pack.The virus is concentrated, inactivated and “split” by disrupting its membranes.
Children 6 to 35 months of age should be given a full dose (0.5 mL) of influenza vaccine. Previously unvaccinated children 6 months to <9 years of age require 2 doses of seasonal influenza vaccine with an interval of atleast 4 weeks. Eligible children <9 years of age who have properly received one or more doses of seasonal influenza vaccine in the past are recommended to receive one dose per season thereafter.
1 Dose, 5 Dose
VAXIGRIP should not be given to persons with known anaphylactic hypersensitivity reactions to egg proteins (eggs or egg products), chicken proteins, or any other component of the vaccine including traces (formaldehyde, octoxinol 9 (Triton X-100) and neomycin). Immunisation should not be performed during a febrile or acute illness.